Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 9, 2024 -- For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs), the competitive telomerase inhibitor imetelstat leads to durable red blood cell (RBC) transfusion independence, according to a study published online Dec. 1 in The Lancet.
Uwe Platzbecker, M.D., from University Hospital Leipzig in Germany, and colleagues compared the RBC transfusion independence rate with imetelstat versus placebo in patients with RBC transfusion-dependent LR-MDS in a double-blind trial conducted at 118 sites. Overall, 178 patients (aged 18 years and older) with ESA-relapsed, ESA-refractory, or ESA-ineligible LR-MDS were enrolled and randomly assigned to imetelstat or placebo (118 and 60, respectively), administered every four weeks as a two-hour intravenous infusion.
Patients were followed for a median of 19.5 and 17.5 months in the imetelstat and placebo groups, respectively. The researchers found that 40 and 15 percent of patients had an RBC transfusion independence of at least eight weeks in the imetelstat and placebo groups, respectively. Of the patients receiving imetelstat and placebo, 91 and 47 percent, respectively, had grade 3 to 4 treatment-emergent adverse events, with the most common events being neutropenia and thrombocytopenia for those taking imetelstat. There were no reports of treatment-related deaths.
"Taken together, IMerge phase 3 results validate the observations from the phase 2 part and show that imetelstat provides clinically significant benefit to a heavily transfusion-dependent LR-MDS patient population," the authors write.
Janssen Research & Development and Geron Corporation funded the trial before and after April 18, 2019, respectively. Geron manufactures imetelstat.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Review Explores Cutaneous Manifestations of Myelodysplastic Syndrome
FRIDAY, April 19, 2024 -- Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and...
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
WEDNESDAY, Feb. 21, 2024 -- Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell...
Cumulative Radiation Dose From CT in Young People Linked to Malignancy Risk
TUESDAY, Nov. 28, 2023 -- Cumulative radiation dose to the bone marrow as a result of computed tomography (CT) examinations in individuals aged younger than 22 years is associated...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.